SCHEMBL3753300

SCHEMBL3753300

Cc1cccc(CN2CCC(C(=O)c3ncco3)CC2)n1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.59
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KCNH2 Q12809 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751175 0.84 L3MBTL1 (0.64) FAAHKMT2AKDM4ESMN1; SMN2L3MBTL1
SCHEMBL4174692 0.82 FAAH (0.70) FAAH
SCHEMBL3759855 0.82 FAAH (0.64) FAAHL3MBTL1
SCHEMBL3759718 0.81 FAAH (0.58) FAAHL3MBTL1
SCHEMBL3743528 0.81 FAAH (0.58) FAAHKMT2AL3MBTL1LMNA
SCHEMBL3748295 0.81 FAAH (0.69) FAAHKMT2ASMN1; SMN2MEN1
SCHEMBL3747551 0.81 FAAH (0.57) FAAHL3MBTL1
SCHEMBL3747543 0.81 FAAH (0.60) FAAHKMT2AMAPTKDM4EL3MBTL1
SCHEMBL3747613 0.80 FAAH (0.69) FAAHKMT2AMAPTKDM4EMEN1
SCHEMBL3749375 0.80 FAAH (0.67) FAAHKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US claimed
EP-2023728-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2009-02-18 EP claimed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO claimed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
EP-2023728-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2009-02-18 EP disclosed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase FAAH, FAAH2, APEH FAAH 1/4885KMT2A 536/4885MAPT 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.